Exact tests using binary data in adaptive two or multi-stage designs

Abstract

When establishing an effective treatment with binary data in a two-stage design, one-sided tests for a proportion p are employed. Researchers use the parameter configuration at the boundary of the null hypothesis space to determine a rejection region and an optimal design. However, it is unclear whether the (maximum) Type I error rate is achieved at the boundary especially when the sample size in stage 2 varies. In this paper, we first prove that this is true for a large family of tests in adaptive two-stage designs by showing that any test in the family has a nondecreasing power in p and then derive optimal designs. Second, similar results are established for m-stage designs with m > 2. Supplementary materials for this article are available online.

Keywords

Binomial distribution phase II clinical trial power sample size Type I error rate

Get full access to this article

View all access options for this article.

References

Jung

SH.

Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.

Contemporary Clin Trials 2015; 42: 9–17.

Banerjee

Tsiatis

AA.

Adaptive two-stage designs in phase II clinical trials.

Stat Med 2006; 25: 3382–3395.

Gehan

EA.

The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent.

J Chronic Dis 1961; 13: 346–353.

Simon

Optimal two-stage designs for phase II clinical trials.

Control Clin Trials 1989; 10: 1–10.

Shan

Wilding

Hutson

, et al. Optimal adaptive two-stage designs for early phase II clinical trials. Stat Med 2016; 35: 1257–1266.

Escudier

Grnwald

Ravaud

, et al. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer. Clin Cancer Res 2014; 20: 3012–3022.

Englert

Kieser

Optimal adaptive two-stage designs for phase II cancer clinical trials.

Biometric J 2013; 55: 955–968.

Jin

Wei

A new adaptive design based on Simon’s two-stage optimal design for phase II clinical trials.

Contemporary Clin Trials 2012; 33: 1255–1260.

Sleijfer

Ray-Coquard

Papai

, et al. Pazopanib, a Multikinase Angiogenesis Inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a Phase II Study from the European Organisation for Research and Treatment of CancerSoft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol 2009; 27: 3126–3132.

10.

Chen

Shan

Optimal and minimax three-stage designs for phase II oncology clinical trials.

Contemporary Clin Trials 2008; 29: 32–41.

11.

Ivanova

Paul

Marchenko

, et al. Nine-year change in statistical design, profile, and success rates of Phase II oncology trials. J Biopharmaceut Stat 2016; 26: 141–149.

12.

Fleming

TR.

One-sample multiple testing procedures for phase II clinical trials.

Biometrics 1982; 38: 143–151.

13.

Yin

Wang

Zhang

On construction of single-arm two-stage designs with consideration of both response and toxicity.

Biometric J 2019; 61: 1462–1476.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.01 MB

0.00 MB